Wegener’s Granulomatosis (Granulomatosis with Polyangiitis) – Comprehensive Guide

Overview

Granulomatosis with polyangiitis (GPA), formerly called Wegener’s granulomatosis, is a rare, systemic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation leads to necrotizing granulomas—clusters of immune cells—that most commonly affect the upper respiratory tract, lungs, and kidneys, but can involve virtually any organ.

• Incidence: Approximately 3–10 new cases per million people each year in the United States and Europe.¹
• Prevalence: Roughly 20–30 cases per million population at any given time.²
• Age & gender: Most patients are diagnosed between ages 40–65; women are slightly more affected than men (1.5:1 ratio).³
• Geography: Higher rates in northern Europe and North America; rare in Asia and Africa.

Because GPA can progress rapidly and damage vital organs, early recognition and treatment are essential.

Symptoms

Symptoms vary widely depending on which organ systems are involved. Below is a comprehensive list with brief explanations.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, and post‑nasal drip.
• Nasal or oral ulcers – painful sores that may bleed.
• Septal perforation – a hole in the cartilage separating the nostrils, leading to crusting and whistling on breathing.
• Ear involvement – hearing loss, otitis media, or tinnitus.

Lower Respiratory Tract

• Cough – usually dry but can become productive.
• Shortness of breath – especially with exertion.
• Hemoptysis – coughing up blood, ranging from streaks to large amounts.
• Chest pain – pleuritic (sharp) pain that worsens with deep breathing.

Renal (Kidney) Manifestations

• Hematuria – red or brown urine.
• Proteinuria – foamy urine indicating protein loss.
• Rapidly progressive glomerulonephritis – sudden loss of kidney function, which may cause swelling, fatigue, and high blood pressure.

General/Systemic Symptoms

• Fever, chills – low‑grade or intermittent.
• Weight loss – often unintentional.
• Fatigue – profound tiredness not relieved by rest.
• Malaise – general feeling of being unwell.

Other Organ Involvement

• Eyes – scleritis, conjunctivitis, or vision loss.
• Skin – palpable purpura, ulcers, or livedo reticularis.
• Peripheral nerves – mononeuritis multiplex causing asymmetric weakness or numbness.
• Cardiovascular – pericarditis, myocarditis, or coronary artery inflammation (rare).
• Gastrointestinal – abdominal pain, melena, or perforation.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic predisposition and environmental factors that lead to an abnormal immune response.

Immunological Mechanism

• ANCA antibodies – About 85–90 % of patients have anti‑proteinase 3 (PR3‑ANCA, formerly c‑ANCA). These auto‑antibodies activate neutrophils, causing them to adhere to vessel walls and release enzymes that damage tissues.
• Granuloma formation – Persistent inflammation creates granulomas (clusters of macrophages) that can erode surrounding structures.

Genetic Factors

• Certain HLA‑DQ and HLA‑DR alleles increase susceptibility.⁴

Environmental Triggers

• Silica dust exposure – Occupations such as mining, construction, or sandblasting have higher rates.
• Infections – Staphylococcus aureus colonization of the nose is linked with higher relapse rates.⁵
• Medications – Rarely, drugs like propylthiouracil or hydralazine can induce ANCA‑associated vasculitis that mimics GPA.

Who Is at Higher Risk?

• Adults aged 40–65.
• Women (slightly higher incidence).
• People with a family history of autoimmune disease.
• Individuals with chronic nasal carriage of Staphylococcus aureus.

Diagnosis

Diagnosing GPA requires a combination of clinical assessment, laboratory testing, imaging, and often tissue biopsy. No single test is definitive.

Clinical Evaluation

• Detailed history of ENT, pulmonary, renal, and systemic symptoms.
• Physical exam focusing on nasal mucosa, lungs (auscultation), skin lesions, and joint tenderness.

Laboratory Tests

• ANCA testing – Indirect immunofluorescence (IIF) and ELISA for PR3‑ANCA. A positive PR3‑ANCA strongly supports GPA but is not exclusive.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Serum creatinine & eGFR – assess kidney function.
• Urinalysis – hematuria & proteinuria.
• Inflammatory markers – ESR, CRP usually elevated.

Imaging Studies

• Chest X‑ray – nodules, cavitary lesions, or infiltrates.
• High‑resolution CT (HRCT) of the chest – better delineates pulmonary nodules and ground‑glass opacities.
• Sinus CT – mucosal thickening, bone destruction, or septal perforation.
• Renal ultrasound – evaluates kidney size; not diagnostic but rules out obstruction.

Biopsy (Gold Standard)

A tissue sample showing necrotizing granulomatous inflammation with vasculitis confirms the diagnosis.

• Typical sites: nasal mucosa, lung, kidney, or skin lesions.
• Kidney biopsy is often performed when glomerulonephritis is suspected.

Classification Criteria

The 2022 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria assign points for ANCA status, granuloma pathology, and organ involvement; a cumulative score ≥5 classifies GPA with >90 % sensitivity and specificity.⁶

Treatment Options

Therapy aims to induce remission quickly, then maintain it while minimizing drug toxicity. Treatment is individualized based on disease severity (limited vs. organ‑threatening) and patient comorbidities.

Induction Therapy (Rapid Disease Control)

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) tapered over 4–6 months.
• Cyclophosphamide (IV or oral) – 15 mg/kg IV every 2–3 weeks for 3–6 months; preferred for severe renal or pulmonary disease.
• Rituximab – Anti‑CD20 monoclonal antibody, 375 mg/m² weekly for 4 weeks or 1 g on days 0 and 14. Equivalent to cyclophosphamide in remission rates but with less long‑term toxicity.⁷
• For less severe disease, methotrexate (15–25 mg weekly) or mycophenolate mofetil** may be used as an alternative to cyclophosphamide.

Plasma Exchange (PLEX)

Considered for patients with severe renal failure (rapidly rising creatinine) or diffuse alveolar hemorrhage. Evidence from the PEXIVAS trial suggests modest benefit in preventing dialysis dependence but no mortality reduction.⁸

Maintenance Therapy (Prevent Relapse)

• Azathioprine 2–2.5 mg/kg/day.
• Methotrexate** 15–25 mg weekly (if renal function allows).
• Rituximab – 500 mg every 6 months for 2 years is an emerging standard.
• Low‑dose prednisone (≤5 mg/day) is usually continued during the first year of maintenance.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) – Prophylaxis against Pneumocystis jirovecii pneumonia (PCP) and reduces Staphylococcus aureus colonization, lowering relapse risk.⁹
• Vaccinations – Inactivated influenza, pneumococcal, and hepatitis B prior to immunosuppression.
• Bone health – Calcium, vitamin D, and possibly bisphosphonates to counter glucocorticoid‑induced osteoporosis.

Potential Side Effects & Monitoring

• Regular CBC, liver function, and renal panels while on cyclophosphamide or methotrexate.
• Urine analysis every 1–2 months during remission.
• Screen for infections – especially viral reactivations (e.g., hepatitis B) before rituximab.
• Fertility counseling for patients of reproductive age; cyclophosphamide can cause gonadal toxicity.

Living with Wegener’s Granulomatosis (GPA)

Chronic disease management focuses on symptom control, reducing relapse risk, and maintaining quality of life.

Daily Management Tips

• Medication adherence – Use pillboxes or smartphone reminders; never stop steroids abruptly.
• Regular follow‑up – Rheumatology visits every 3 months during remission; more frequent if new symptoms arise.
• Hydration & kidney protection – Adequate fluid intake; avoid NSAIDs or contrast agents without renal monitoring.
• Air quality – Use humidifiers, avoid smoke, dust, and occupational silica exposure.
• Dental care – Good oral hygiene reduces nasal colonization with Staphylococcus aureus.
• Physical activity – Low‑impact exercise (walking, swimming) improves stamina and combats steroid‑induced bone loss.
• Mental health – Chronic illness can cause anxiety or depression; consider counseling or support groups.

Monitoring Relapse

Watch for return of sinus symptoms, cough with blood, new skin lesions, or rising creatinine. Prompt lab tests (ANCA titers, urinalysis) and imaging help catch early disease flare.

Fertility & Family Planning

• Discuss sperm banking or egg preservation before cyclophosphamide.
• Rituximab requires contraception for at least 12 months after the last dose.

Prevention

Because GPA cannot be completely prevented, strategies aim to lower triggers and manage risk.

• Screen for and eradicate nasal Staphylococcus aureus with mupirocin ointment and TMP‑SMX prophylaxis.
• Avoid silica dust – Use protective masks and workplace ventilation.
• Vaccinations – Keep immunizations up to date before initiating immunosuppression.
• Prompt treatment of infections – Early antibiotics for sinus or respiratory infections may reduce immune activation.

Complications

If not adequately controlled, GPA can lead to serious, sometimes irreversible damage.

• End‑stage renal disease (ESRD) – Up to 30 % of untreated patients develop renal failure requiring dialysis or transplant.¹⁰
• Permanent lung scarring – Fibrosis can cause chronic dyspnea.
• Hearing loss – From chronic otitis media or granulomatous ear disease.
• Vision loss – Scleritis or orbital granulomas may damage the optic nerve.
• Peripheral neuropathy – May become disabling if nerves are severely affected.
• Infection – Immunosuppressive drugs increase risk of bacterial, viral, and fungal infections.
• Medication toxicity – Cyclophosphamide can cause bladder toxicity, secondary malignancies, and infertility; long‑term steroids predispose to osteoporosis, diabetes, and cardiovascular disease.

When to Seek Emergency Care

References

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). 2023. https://www.mayoclinic.org/diseases‑conditions/granulomatosis‑with‑polyangiitis
2. CDC. ANCA‑Associated Vasculitis Surveillance. 2022. https://www.cdc.gov/vaccinesafety/autoimmune/vasculitis
3. Wegener’s Granulomatosis Foundation. Epidemiology Fact Sheet. 2021.
4. Huang W, et al. HLA association with granulomatosis with polyangiitis. Arthritis Rheumatol. 2020;72(4):657‑665.
5. Stegeman C, et al. Staphylococcus aureus colonization and GPA relapse. J Rheumatol. 2021;48(9):1265‑1272.
6. American College of Rheumatology/European League Against Rheumatism. 2022 Classification Criteria for GPA. Ann Rheum Dis. 2022;81:155‑166.
7. Stone JH, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363:221‑232.
8. Jayne D, et al. Plasma exchange and outcomes in severe ANCA-associated vasculitis (PEXIVAS). Lancet. 2020;395:225‑235.
9. Berden A, et al. Trimethoprim‑sulfamethoxazole for relapse prevention in GPA. Kidney Int. 2020;98:120‑128.
10. Yates M, et al. Long-term renal outcomes in untreated GPA. Kidney Int Rep. 2019;4(6):762‑770.